What Medinfar does

Grupo Medinfar is a Portuguese-origin pharmaceutical company founded in 1970, headquartered in Amadora, Portugal, with direct operations in Portugal and Morocco and export reach to 70+ countries. The group manufactures and markets both proprietary and partnered pharmaceutical brands across therapeutic areas including Consumer Health, Dermatology, Endocrinology, Respiratory, and Veterinary, holding more than 800 product registrations worldwide and producing 40 million units in 2023. Its corporate structure spans wholly-owned subsidiaries covering manufacturing (Medinfar Manufacturing S.A.), consumer health (Medinfar Consumer Health Lda.), veterinary and immunological products (Medinfar Sorológico S.A.), generics (Genéricos Portugueses Lda.), and shared services (Medinfar Serviços Lda.). Medinfar holds the #1 position in Portugal in the Consumer Health and Dermatology category and ranks 3rd largest among Portugal's top 5 pharmaceutical companies.

The business model combines four revenue streams: own-brand pharmaceutical products (primarily in Consumer Health and Dermatology), partnered-brand manufacturing and marketing, contract manufacturing for third-party clients, and international licensing-out of products through local partners who manage in-country commercialization. Manufacturing is anchored by an industrial facility in Condeixa-a-Nova currently undergoing a €33.8M modernization under the Portugal 2030/COMPETE 2030 program, with €5.07M of EU co-financing, targeting €63M in post-expansion sales and the creation of 66 new jobs. In-house R&D focuses on new formulations, production processes, and analytical methodologies. Quality and regulatory infrastructure includes ISO 9001, 14001, and 45001 certifications, GDPR compliance, and a comprehensive pharmacovigilance system reporting to INFARMED, DGAV, and DGS.

Go-to-market is sales-led through direct commercial teams in Portugal and Morocco, with channel partnerships and licensing-out arrangements extending reach into 70+ countries. In 2020 the company acquired the Medicamenta Business Unit and in 2023 received external investment through Explorer Investments to fund R&D and production process improvements, signaling continued capital-supported growth in established therapeutic categories and selected adjacent areas such as Endocrinology and Respiratory.

Name

Medinfar

Legal name

Laboratório Medinfar – Produtos Farmacêuticos, S.A.

Website

https://medinfar.pt

Company type

Private

Founded year

1970

Operating status

Operating

Headcount range

11–50 employees

Short description

Grupo Medinfar is a Portuguese pharmaceutical company founded in 1970 that manufactures and markets own-brand and partnered pharmaceutical products across Consumer Health, Dermatology, Endocrinology, Respiratory, and Veterinary therapeutic areas, distributing to 70+ countries through 800+ product registrations.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Pharmaceutical manufacturing
• Consumer health products
• Dermatology pharmaceuticals
• Contract manufacturing services
• Veterinary pharmaceuticals

Headquarters

HQ city

Amadora

HQ country

Portugal

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Own Brand Pharmaceutical Products: Manufacturing and marketing of company's own pharmaceutical brands, primarily in Consumer Health and Dermatology categories
2. Partnered Brand Products: Manufacturing and marketing of products under partnership arrangements with other pharmaceutical companies
3. Contract Manufacturing: Manufacturing pharmaceutical products for third-party clients under contract manufacturing agreements
4. International Licensing Out: Licensing products to partners in international markets where Medinfar manages regulatory registrations

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Medinfar is a Portuguese pharmaceutical company that manufactures and markets its own-branded and partnered pharmaceutical products across Consumer Health, Dermatology, Endocrinology, Respiratory and Veterinary therapeutic areas. The group operates an industrial manufacturing unit with Industry 4.0 capabilities, an R&D laboratory for new formulations, and a Qualified Person service, and manages 800+ product registrations in 70+ countries. Beyond branded products, it offers contract manufacturing for third parties and international licensing out of its registered products.

Product overview

Medinfar is a Portuguese pharmaceutical company founded in 1970 that operates as a manufacturer and marketer of both proprietary and partnered pharmaceutical brands. The company operates as a platform of distinct branded products spanning Consumer Health, Dermatology, and specialized therapeutic areas. The portfolio includes branded products such as Trizatek, Otezia, Halibut Derma, Psoril, Halibut MF, Trikare, Oleoban, Xeratop, Provivax, Clique One, PreviPiQ, and Bio Ritmo. Medinfar's business model combines manufacturing capabilities (industrial unit), R&D (pharmaceutical development laboratory, analytical control services, Qualified Person services), and international distribution managing over 800 product registrations worldwide. The company also offers contract manufacturing services and operates in therapeutic areas including Consumer Health, Endocrinology, Respiratory, Dermatology, and Veterinary.

Differentiator

Problem solved

Functional benefit

Products and services

• Trizatek Branded pharmaceutical product marketed by Medinfar, part of the company's portfolio of consumer health and dermatology offerings.
• Otezia Branded pharmaceutical product in Medinfar's portfolio, distributed within Portugal and internationally.
• Halibut Derma Dermatology-focused branded product by Medinfar, positioned within the company's leading Consumer Health and Dermatology category in Portugal.
• Psoril Branded pharmaceutical product by Medinfar, included in the company's dermatology product range.
• Halibut MF Branded pharmaceutical product variant by Medinfar, part of the Halibut product line.
• Trikare Branded pharmaceutical product by Medinfar, included in the company's therapeutic portfolio.
• Oleoban Branded pharmaceutical product by Medinfar, distributed through the company's commercial network.
• Xeratop Branded pharmaceutical product by Medinfar, part of the company's consumer health offerings.
• Provivax Branded pharmaceutical product by Medinfar, included in the company's international product catalog.
• Clique One Branded pharmaceutical product by Medinfar, distributed in Portugal and internationally.
• PreviPiQ Branded pharmaceutical product by Medinfar, part of the company's preventive health portfolio.
• Bio Ritmo Branded pharmaceutical/health product by Medinfar, included in the company's consumer health offerings.
• Contract Manufacturing Services Contract manufacturing service through Medinfar Manufacturing, S.A. for third-party pharmaceutical clients, leveraging the group's industrial unit, Industry 4.0 capabilities, ISO-certified quality systems, and capacity to produce multiple pharmaceutical forms.
• International Licensing Out International licensing of Medinfar-registered pharmaceutical products to local partners who manage commercialization in markets where Medinfar does not operate directly. Medinfar manages 800+ product registrations worldwide supporting this offering.
• Pharmaceutical Development Laboratory (R&D) Pharmaceutical R&D laboratory service within the I&D division, focused on innovation of new products, processes and analytical methodologies, serving as a strategic area for the Group and for development of new solutions for clients.
• Analytical Control Services Pharmaceutical analytical control services provided through the I&D division, supporting quality control, method development and analytical testing for pharmaceutical products.
• Qualified Person Services Qualified Person services providing certified pharmaceutical release oversight in accordance with EU GMP requirements, supporting batch certification and regulatory compliance for manufactured products.

Quantifiable outcome

• 40 million units manufactured in 2023
• +2 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core.

• RESPIRAcoreOthersPartnership with respiratory disease patient association for disease prevention and management, contributing to reduced prevalence of chronic diseases in Portugal through appropriate treatment and counseling.
• MyOBESIDADEcoreOthersPartnership with obesity patient association for disease management and support, addressing chronic disease prevalence in Portugal.
• APDP (Associação Protectora dos Diabéticos de Portugal)coreOthersPartnership with Portuguese diabetes patient association for diabetes management and education, contributing to chronic disease awareness and treatment support.
• International DistributorscoreChannel Partner/ Reseller/ DistributorPartnership network across 70+ countries for export and distribution of Medinfar products, managing local product registrations and commercialization.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Bial: Portuguese-headquartered pharmaceutical company with proprietary R&D and branded prescription products. Comparable to Medinfar as a fellow top-tier Portuguese pharma group competing for domestic market share and pursuing international commercialization.
• Almirall: Spanish dermatology-focused pharmaceutical company with branded prescription and consumer dermatology products across Europe. Directly comparable to Medinfar's dermatology leadership in Iberia and European commercial footprint.
• Faes Farma: Spanish pharmaceutical company with consumer health, OTC and branded prescription products including dermatology and respiratory. Highly comparable business model and Iberian market positioning to Medinfar.
• Galderma: Global dermatology-specialist pharmaceutical company. Comparable as the leading pure-play dermatology peer against which Medinfar's Halibut Derma and Psoril brands compete for shelf and prescription share.

Broad incumbents

• Stada Arzneimittel: European-focused generics and consumer healthcare company with broad portfolio across multiple therapeutic areas. Comparable as a much larger incumbent operating the same branded-generic-plus-consumer-health business model.
• Perrigo: Global consumer healthcare and self-care products company focused on OTC, dermatology and store brands. Comparable as a benchmark for Medinfar's consumer health and OTC strategy at international scale.
• Recordati: European specialty pharmaceutical company with branded prescription and consumer health products. Comparable as a larger European incumbent with overlapping dermatology, endocrinology and respiratory portfolios.
• Towa Pharmaceutical: International generics and contract development/manufacturing organization serving European and global markets. Comparable as a peer in pharmaceutical manufacturing services and generic distribution that competes for the same contract manufacturing opportunities.

Regional players

• Rottapharm: Italian pharmaceutical group with branded consumer health, OTC and specialty products across Europe. Comparable as a Southern European mid-cap pharma with similar diversified therapeutic and consumer health positioning.
• Zambon: Italian pharmaceutical company with branded prescription, consumer health and chemical/pharma services businesses. Comparable as a Southern European pharma with parallel branded-plus-contract manufacturing model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries5 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medinfar